Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Clinical trial NCT03794544 · COMPLETED

Trial details

NCT number: NCT03794544
Sponsor: MedImmune LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Early-stage NSCLC

Start date: 2019-03-08
Primary completion: 2021-01-13
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.